Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

Thomas Frisell; Hannah Bower; Matilda Morin; Eva Baecklund; Daniela Di Giuseppe; Benedicte Delcoigne; Nils Feltelius; Helena Forsblad-d'Elia; Elisabet Lindqvist; Ulf Lindström; Johan Askling

doi:10.1136/ard-2022-223762

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

PDF +
Supplementary
Material

Rheumatoid arthritis

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Frisell T, Bower H, Morin M on behalf of the ARTIS Study group, et al

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

Annals of the Rheumatic Diseases 2023;82:601-610.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password